Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wuxi And Qiagen Form Biomarker Partnership In Shanghai

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - WuXi Pharmatech, China's top contract research organization, and Qiagen, the leading global provider of sample and assay technologies, announced Jan. 11 that they reached an agreement to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets for their respective client bases

You may also be interested in...



Qiagen Forms JV With Shanghai's Bio-X Center For Translational Research In China

Qiagen forms JV with Shanghai Jiao Tong University for translational research to focus on biomarkers, diagnostics for developing drugs specifically for Asians.

China's CRO Industry Pulling Out All Stops In The Year Of The Tiger (Part 1 of 2)

SHANGHAI - By the end of 2009 there were roughly 500 contract research organizations in China, most of which are small registration consultants, and about 150 execute research work. Driven by the trend to offshore R&D work from big pharmas and the double digital growth of the Chinese market, the number of CRO companies is expected to increase further and offer broader services in the upcoming Chinese Year of The Tiger

Qiagen Buys DxS, Boasts "Deepest" Personalized Medicine Testing Pipeline

Qiagen is boasting the "deepest" pipeline of molecular diagnostics for personalized medicine after acquiring test maker DxS for $95 million, plus up to $35 million in milestone payments

Related Content

UsernamePublicRestriction

Register

SC073003

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel